Pharma powerhouse Cipla has delivered a strong start to FY27, reporting consolidated revenue of Rs. 7,119 crore for the quarter ended June 30, 2026, driven by robust growth across key markets, strengthening brands and continued investments in future growth.

 

The company’s One India business recorded its highest-ever quarterly sales, growing 12% year-on-year, while the overall chronic portfolio mix improved to 60.4% in the market. Cipla’s global performance was supported by steady momentum in North America, Africa, Emerging Markets and Europe.

 

Cipla reported quarterly income from operations of Rs. 7,119 crore, EBITDA of Rs. 1,192 crore (16.7%) and profit after tax (PAT) of Rs. 789 crore (11.1%).

 

The company’s R&D investments stood at INR 486 crore during the quarter, accounting for 6.8% of sales, rising 12.3% year-on-year as Cipla accelerated product filings and development initiatives. The company maintained a strong net cash position of Rs. 9,494 crore, with debt largely comprising lease liabilities and working capital requirements.

 

Cipla’s North America business delivered quarterly revenue of $162 million, while Emerging Markets and Europe crossed $100 million in quarterly revenue, registering 5% year-on-year growth in USD terms.

 

In Africa, Cipla’s prescription business retained its No. 2 ranking in the market, with South Africa’s private market business growing ahead of the broader market.

 

Commenting on the results, Achin Gupta, MD and Global CEO, Cipla Ltd., said: "We are pleased to share that we continue to make considerable progress across our focused markets. In Q1FY27, we delivered global revenues of Rs. 7,119 crore.

 

"Our One-India business grew at solid 12% YoY. Branded Prescription business delivered a robust growth, with key therapies outpacing the market, Trade Generics recorded healthy growth and Anchor brands of Consumer Health Business maintained leadership position.

 

"The US business posted a revenue of $ 162 Mn during the quarter. We expect continued sequential growth in North America, supported by upcoming product pipeline. South Africa private business continued to grow faster than the market. 

 

"Emerging Markets and Europe continued its growth trajectory with revenue growth of 5% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front."

 

Cipla’s Branded Prescription business recorded market growth of 15.4%, outperforming the Indian Pharmaceutical Market by 183 basis points. Key therapies, including Respiratory, Urology, Cardiac and Anti-diabetes, posted strong double-digit growth, helping improve the company’s chronic mix.

 

The Trade Generics business reported healthy year-on-year growth, supported by strong distribution execution and new product launches, including three new introductions during the quarter.

 

Cipla’s Consumer Health portfolio continued to maintain leadership across major categories, with flagship brands Nicotex, Omnigel and Cipladine retaining their positions in respective market segments.

 

Cipla’s North America business continued to strengthen its position, with Albuterol ranking No. 1 in the overall US Albuterol MDI market with a 21% market share.

 

During the quarter, Cipla launched gVentolin after receiving regulatory approval in the previous quarter, with commercial shipments underway and volumes expected to rise gradually as supply scales up. The company also expanded its presence in high-growth therapy areas with the launches of Nintedanib and Dapagliflozin.

 

In South Africa’s private market, Cipla recorded secondary growth of 6.5%, ahead of market growth of 5.7%, while maintaining its No. 2 position in the prescription segment.

 

Emerging Markets and Europe continued their growth trajectory, supported by Cipla’s deep market focus strategy. The business delivered 5% year-on-year growth in USD terms, aided by momentum in DTM and B2B categories and sustained margins.

 

Cipla said it will continue focusing on expanding key markets, strengthening flagship brands, investing in its future product pipeline and addressing regulatory priorities.